Skip to main content



28-04-2021 | Oncology | News | Article

AHA issues statement on managing hormonal therapy-related CVD risks

The American Heart Association has released a consensus statement on the management of cardiovascular disease in patients receiving hormonal therapies for breast or prostate cancer.

28-04-2021 | Oncology | News | Article

Cardiovascular AEs of prostate cancer hormone therapies reported

An analysis of the FDA Adverse Event Reporting System has provided detailed insight into cardiovascular adverse events associated with different classes of androgen deprivation therapies.

22-04-2021 | Oncology | News | Article

Limited evidence to link antihypertensive use to cancer

An extensive meta-analysis of individual participant data has not found consistent evidence to indicate that antihypertensive use is associated with an increased risk for cancer.

04-02-2021 | Diabetes | News | Article

High CVD risk at type 2 diabetes diagnosis increasingly common

The proportion of people with new-onset type 2 diabetes who have high cardiovascular risk has increased consistently over time, with a particularly notable rise in the prevalence of cardiometabolic multimorbidity among young people, researchers report.

15-01-2021 | Diabetes | News | Article

SGLT2 inhibition may reduce myocardial extracellular volume

Treatment with the SGLT2 inhibitor empagliflozin is associated with a reduction in myocardial extracellular volume among individuals with type 2 diabetes and coronary artery disease, suggests an analysis of data from the EMPA-HEART CardioLink-6 trial.

08-01-2021 | Oncology | News | Article

Data suggest no causality between osimertinib use, cardiac AEs

A review of data from the osimertinib clinical trials program has not identified a causal relationship between the use of the EGFR–tyrosine kinase inhibitor and cardiotoxicity among patients with advanced non-small-cell lung cancer.

18-12-2020 | Cardiovascular | News | Article

DAPA-CKD: Dapagliflozin renoprotective regardless of underlying CKD etiology

A prespecified analysis of data from the DAPA-CKD trial suggests that add-on treatment with dapagliflozin slows decline in renal function among patients with chronic kidney disease irrespective of the underlying etiology.

18-12-2020 | Oncology | News | Article

Researchers call for increased awareness of cardiac events among ICI users

People receiving immune checkpoint inhibitor therapy for lung cancer or malignant melanoma have a significantly increased risk for cardiovascular events, observational study data show.

04-12-2020 | Rheumatology | News | Article

Even low-dose oral glucocorticoid use associated with increased CV risk

UK research has identified a “strong dose-dependent” association between oral glucocorticoid use and CVD risk among people with immune-mediated diseases, with an increased risk seen even at doses of less than 5 mg/day.

04-12-2020 | Diabetes | News | Article

EMPA-REG OUTCOME: Empagliflozin reduces total CV burden in type 2 diabetes

Empagliflozin reduces the total burden of cardiovascular complications and all-cause hospitalization in people with type 2 diabetes and atherosclerosis, show data from the EMPA-REG OUTCOME trial.

27-11-2020 | Diabetes | News | Article

Healthy lifestyle mitigates elevated heart disease risk in people with type 2 diabetes

People with type 2 diabetes have around a fourfold increased risk for heart disease relative to those without, but having a healthy lifestyle may lessen this risk, researchers report.

26-11-2020 | Diabetes | News | Article

Type 2 diabetes linked to increased CVD risk even without CV risk factors

The risk for cardiovascular disease is at least one-fifth higher in people with type 2 diabetes than in those without diabetes, even when risk factors are optimally controlled, study findings indicate.

25-11-2020 | Diabetes | News | Article

Empagliflozin LV remodeling not reliant on glucose lowering

The EMPATROPISM trial, which enrolled people without type 2 diabetes, shows reversal of left ventricular remodeling in patients with heart failure and reduced ejection fraction given empagliflozin rather than placebo.

25-11-2020 | Diabetes | News | Article

More than half of people with type 2 diabetes at very high CV risk

A Spanish cross-sectional study suggests that a substantial proportion of people with type 2 diabetes are at very high risk for fatal cardiovascular events and could be considered as coronary artery disease equivalent.”

24-11-2020 | Diabetes | News | Article

Age has no impact on CV outcomes with linagliptin vs glimepiride

Cardiovascular event rates do not differ significantly among people with type 2 diabetes treated with linagliptin or glimepiride regardless of age, but those who receive linagliptin have lower risks for falls and hypoglycemia, CAROLINA trial data show.

19-11-2020 | Diabetes | News | Article

Targeting fat mass, central adiposity may reduce HF risk in type 2 diabetes

The risk for heart failure falls significantly with reductions in fat mass and waist circumference in overweight or obese people with type 2 diabetes, shows an analysis of data from the Look AHEAD trial.

18-11-2020 | Diabetes | News | Article

Empagliflozin shows heart failure benefits regardless of HbA1c

Empagliflozin reduces the risk for adverse cardiovascular outcomes in people with heart failure and a reduced ejection fraction irrespective of their baseline glycated hemoglobin level, EMPEROR-Reduced trial data show.

17-11-2020 | Diabetes | News | Article

SOLOIST-WHF: Sotagliflozin beneficial when started shortly after acute heart failure episode

Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.

17-11-2020 | Diabetes | News | Article

​​​​​​​Sotagliflozin SCORED cardiovascular risk reduction in people with type 2 diabetes, CKD

Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.

28-09-2020 | Diabetes | News | Article

Cardioprotective measures neglected in young-onset type 2 diabetes

People with type 2 diabetes, especially young people, do not receive treatment for hypertension and dyslipidemia in a timely manner, even when they have high cardiovascular risk, study results show.

Image Credits